6 results
Primary Objective: * To confirm the safety profile of plerixafor to mobilise stem cells when used in patients with lymphoma or MM who are eligible to undergo treatment with an autologous haematopoietic stem cell transplantSecondary Objectives:* To…
Primary objectiveTo determine the feasibility of plerixafor 320 *g/kg subcutaneously to harvest a sufficient number of CD34+ peripheral blood stem cells/kg recipient body weight. Feasibilty is defined as a minimum of 2.0x10^6/kg CD34+ cells in one…
In this study, plerixafor, the study drug, will be given in addition to GCSF to see if it works the same way in children as in adults.
To demonstrate that Plerixafor is able to reduce the need for invasive mechanical ventilation or death in severe COVID-19 patients admitted in Intensive Care Unit (ICU)
The primary objective will be evaluating the difference in detection of new AF between the intervention practices (yearly 7 days AF screening with continuous heart rhythm monitoring) and control practices (care as usual) over three years of follow-…
Primary• To evaluate the safety and tolerability of AMG 910 in adult subjects. • To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)Secondary• To characterize the PK of AMG 910• To evaluate preliminary anti-tumor…